



Full English text available at
www.actasdermo.org

RESIDENT'S FORUM

[Translated article] RF-Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Dermatology



FR-Terapia de células T con receptores quiméricos de antígenos (CAR-T) en dermatología

E.L. Pinto-Pulido ^{a,*}, G. López de Hontanar-Torres^b

^a Servicio de Dermatología, Hospital Universitario Príncipe de Asturias, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain

^b Servicio de Hematología, Hospital Universitario Príncipe de Asturias, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain

KEYWORDS

CAR-T therapy;
Immunotherapy;
Dermatologic oncology;
Autoimmune diseases;
Cutaneous adverse effects

PALABRAS CLAVE

Terapia CAR-T;
Inmunoterapia;
Oncología dermatológica;
Enfermedades autoinmunes;
Efectos adversos cutáneos

The development of chimeric antigen receptor T-cell (CAR-T) therapies is revolutionizing the treatment of hematological malignancies. At the same time, their utility is being investigated in other cancers and autoimmune diseases¹ where dermatologists play a fundamental role.

CAR-T cells are autologous T cells transduced with a chimeric receptor targeted against an antigen. T cells are collected from the patient via peripheral blood apheresis and using a viral vector are transduced with a gene that targets a tumor antigen. Afterwards, the patient receives lymphodepleting chemotherapy, and CAR-T cells are infused; these cells are expected to engraft and expand. CD19-targeted CAR-T cells have demonstrated efficacy in the treatment of B-cell hematological neoplasms.² Specific toxicities have been reported, such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and hematological toxicity. Furthermore, the use of allogeneic CAR-T and CAR-NK cells is also being studied.³

Cutaneous lymphomas often exhibit a less aggressive behavior, allowing for local therapies. However, their management in advanced cases (generally T-cell lymphomas) is complex. Unfortunately, CAR-T cells have not been successfully developed for T-cell malignancies due to similarities between healthy and tumor T cells, which lead to the potential development of T-cell aplasia or contamination of the product (obtaining CAR-T cells that include tumor cells).⁴ As for melanoma, despite being a significant area of research, only the results of one clinical trial have been published. It included 3 patients refractory to, at least, 2 lines of immunotherapy who received CAR-T cells targeting the oncogene MET. All discontinued treatment due to progression.⁵ Other

DOI of original article:

<https://doi.org/10.1016/j.ad.2024.10.073>

* Corresponding author.

E-mail address: elucia.pinto95@gmail.com (E.L. Pinto-Pulido).

<https://doi.org/10.1016/j.ad.2025.07.017>

0001-7310/© 2025 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

tumor targets are being investigated, such as tyrosinase-related protein 1 (TRP1), which has shown antitumor activity in mice and patient-derived preclinical models.⁶

Beyond oncology, this therapy is emerging as a promise in autoimmune diseases. A recent article has been published on patients with severe systemic lupus erythematosus (SLE; $n=8$), idiopathic inflammatory myositis (IIM; $n=3$), and systemic sclerosis (SSc; $n=4$) all treated with CD19-targeted CAR-T cells. All had cutaneous involvement except for 2 patients with IIM. At 6 months, complete remission was achieved in all patients with SLE or IIM, and a reduction in pulmonary and cutaneous activity was reported in patients with SSc. All remained stable during follow-up (median, 15 months, range, 4–29), without other immunosuppressive treatments. Remission of pathological autoantibodies was observed, even after complete B-cell reconstitution, supporting the idea that CAR-T cells may induce an immunological reset, leading to long-term sustained remission.¹

Cutaneous adverse effects with this therapy appear in 4–36% of patients, depending on the consulted series. Most consist of mild/moderate maculopapular rashes. However, bullous and petechial eruptions have been reported, and some patients require systemic treatment. Their etiopathogenesis is uncertain, possibly linked to CRS or cross-reactivity with cutaneous antigens similar to the CAR-T target, though their prognostic implication has not yet been studied.²

Funding

None declared.

References

1. Müller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Völkl S, et al. CD19 CAR T-cell therapy in autoimmune disease – a case series with follow-up. *N Engl J Med.* 2024;390:687–700, <http://dx.doi.org/10.1056/NEJMoa2308917>.
2. Nusbaum KB, Dulmage B, Choi JN, Jaglowski SM, Korman AM. Cutaneous manifestations of chimeric antigen receptor T-cell therapy: an introduction for dermatologists. *J Am Acad Dermatol.* 2022;87:597–604, <http://dx.doi.org/10.1016/j.jaad.2021.07.017>.
3. Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. *Nat Med.* 2024;30:772–84, <http://dx.doi.org/10.1038/s41591-023-02785-8>.
4. To V, Evtimov VJ, Jenkin G, Pupovac A, Trounson AO, Boyd RL. CAR-T cell development for cutaneous T cell lymphoma: current limitations and potential treatment strategies. *Front Immunol.* 2022;13:968395, <http://dx.doi.org/10.3389/fimmu.2022.968395>.
5. Shah PD, Huang AC, Xu X, Orłowski R, Amaravadi RK, Schuchter LM, et al. Trial of autologous RNA-electroporated cMET-directed CAR T cells administered intravenously in patients with melanoma and breast carcinoma. *Cancer Res Commun.* 2023;3:821–9, <http://dx.doi.org/10.1158/2767-9764.CRC-22-0486>.
6. Jilani S, Saco JD, Mugarza E, Pujol-Morcillo A, Chokry J, Ng C, et al. CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes. *Nat Commun.* 2024;15:1244, <http://dx.doi.org/10.1038/s41467-024-45221-2>.